Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.08 AUD
Change Today 0.00 / 0.00%
Volume 0.0
ACL On Other Exchanges
As of 2:10 AM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

alchemia ltd (ACL) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/11/14 - A$0.68
52 Week Low
05/4/15 - A$0.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALCHEMIA LTD (ACL)

Related News

No related news articles were found.

alchemia ltd (ACL) Related Businessweek News

No Related Businessweek News Found

alchemia ltd (ACL) Details

Alchemia Limited, a biotechnology company, develops human therapeutic products based on its proprietary drug discovery, drug targeting, and synthesis technologies in Australia and the United States. Its technologies include HyACT, a platform technology that uses the non-toxic and naturally occurring carbohydrate, hyaluronic acid as a drug delivery vehicle for a range of approved anti-cancer therapeutics; and Versatile Assembly on Stable Templates technology, a small molecule drug discovery technology. The company also provides generic fondaparinux, an anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. In addition, it develops HA-Irinotecan that is in Phase III clinical trials for the treatment of metastatic colorectal cancer, as well as in the phase II investigator-sponsored trials that focuses on small cell lung cancer. The company has collaboration agreements with AstraZeneca AB to discover and develop novel small molecules against multiple targets; Merck Serono to develop HA-Irinotecan in combination with therapeutic antibody, Erbitux (cetuximab), for patients with metastatic colorectal cancer; and IMBcom Asset Management Company for conducting research based upon certain voltage gated ion channel biological targets and library compounds, as well as with University of Queensland for ion channel drug discovery. Alchemia Limited also has research agreement with Monash University; and Cancer Research Technology Limited. The company was founded in 1995 and is headquartered in Brisbane, Australia.

29 Employees
Last Reported Date: 08/29/14
Founded in 1995

alchemia ltd (ACL) Top Compensated Officers

Chief Scientific Officer and Vice President o...
Total Annual Compensation: A$235.7K
Group Financial Controller
Total Annual Compensation: A$193.4K
Vice President of Drug Discovery
Total Annual Compensation: A$224.3K
Vice President of Intellectual Property & Tec...
Total Annual Compensation: A$223.9K
Compensation as of Fiscal Year 2014.

alchemia ltd (ACL) Key Developments

Alchemia Limited(ASX:ACL) dropped from S&P/ASX All Ordinaries Index

Alchemia Limited(ASX:ACL) dropped from S&P/ASX All Ordinaries Index

Alchemia Limited Reports Consolidated Earnings Results for the Six Months Ended December 31, 2014

Alchemia Limited reported consolidated earnings results for the six months ended December 31, 2014. For the period, the company’s revenue from continuing operations was AUD 6,829,000 against AUD 5,035,000 a year ago. Loss from continuing operations before income tax was AUD 18,044,000 against AUD 5,672,000 a year ago. Net loss from continuing operations was AUD 15,759,000 or 4.9 diluted per share against AUD 5,474,000 or 1.7 diluted per share a year ago. Net cash flows used in operating activities was AUD 898,000 against AUD 3,685,000 a year ago. Payments for property, plant, equipment and other assets was AUD 2,000 against AUD 247,000 a year ago.

Alchemia Limited Announces Sales Results for the Quarter Ended December 31, 2014

Alchemia Limited announced sales results for the quarter ended December 31, 2014. For the quarter, the company reported gross revenue of AUD 1.91 million from its profit share on US sales of its generic anti-coagulant drug fondaparinux. The company will receive AUD 1.29 million as net revenue, after deducting AUD 0.62 million for its contribution to yield and cost of goods improvement activities. This payment represents the final installment of the company’s contribution to these activities. Therefore, in all future quarters, there will be no further deductions to the gross revenue for process improvements.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACL:AU A$0.08 AUD 0.00

ACL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACL.
View Industry Companies

Industry Analysis


Industry Average

Valuation ACL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALCHEMIA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at